Moleculin Biotech, Inc. filings document regulatory disclosures for a Delaware clinical-stage pharmaceutical company focused on drug development and commercialization. Recent Form 8-K reports cover Regulation FD releases, investor presentations, financial results, clinical and preclinical updates for Annamycin, and intellectual-property matters involving liposomal Annamycin.
The filing record also includes capital-structure and governance disclosures tied to warrant exercise inducement arrangements, warrant-related share issuance, and stockholder voting matters. Definitive proxy materials and voting results describe special-meeting proposals, including Nasdaq-related approval for warrant shares and charter-related governance items, while exhibit filings attach press releases, presentation materials, and other public-company disclosures.
Moleculin Biotech (MBRX) disclosed an insider equity transaction by its Chief Science Officer. On 11/04/2025, 8,750 restricted stock units converted to common stock, and 2,131 shares were withheld at $0.497 for taxes upon vesting. Following these transactions, the reporting person beneficially owned 16,771 shares directly. Derivative holdings show 95,508 restricted stock units remaining. The RSUs relate to a 35,000-unit grant made on November 4, 2024, scheduled to vest in four equal annual installments beginning on the first anniversary of the grant date.
Moleculin Biotech (MBRX) reported an insider equity event by its CEO and President/Director. On 11/04/2025, 28,750 shares of common stock were acquired upon the vesting and conversion of restricted stock units (transaction code M). The filing also shows 7,001 shares were disposed (code F) to cover taxes at $0.497 per share.
Following these transactions, the executive directly beneficially owned 765,356 shares of common stock. The derivative holdings section lists 2,380,731 derivative securities beneficially owned after the reported transaction. The RSUs convert one-for-one into common stock, and the underlying grant from November 4, 2024 totals 115,000 RSUs vesting in four equal annual installments beginning on the first anniversary.
Moleculin Biotech (MBRX) reported an officer equity transaction. On 11/04/2025, Chief Financial Officer Jonathan P. Foster settled 20,625 restricted stock units that converted into common stock on a one-for-one basis (code M).
To cover taxes upon vesting, 5,023 shares were withheld at a price of $0.497 per share. Following these transactions, Mr. Foster directly owns 303,189 shares of Moleculin common stock.
The RSUs relate to an award granted on November 4, 2024 of 82,500 RSUs, vesting in four equal annual installments beginning on the first anniversary of the grant date.
Moleculin Biotech (MBRX) furnished a corporate presentation under Regulation FD (Item 7.01), included as Exhibit 99.1. The presentation is posted on the company’s website and the exhibit is being furnished, not filed, which means it is not incorporated into other Securities Act or Exchange Act filings unless expressly stated.
Moleculin Biotech, Inc. (MBRX) announced a new patent grant in Australia. The company reported that IP Australia has granted Patent No. 2024203598 titled “PREPARATION OF PRELIPOSOMAL ANNAMYCIN LYOPHILIZATE,” covering certain preliposomal Annamycin lyophilizates with improved stability and high purity.
The patent’s base term currently extends until June 2040, with potential extension to account for time required to fulfill regulatory approval requirements. The company furnished a press release with further details as an exhibit.
Moleculin Biotech reported that it entered into an agreement with Atlantic Health System to begin an investigator-initiated Phase 1B/2 single-arm study of Annamycin for third-line treatment of advanced pancreatic cancer. This design allows a clinical site to lead the study while evaluating Annamycin in a heavily pretreated setting.
The announcement was furnished under Item 7.01, with the related press release included as Exhibit 99.1. Because it is furnished rather than filed, it is intended for informational purposes. No financial terms or clinical timelines are included in the disclosure.
Moleculin Biotech, Inc. (MBRX) reported stockholder voting results from its Special Meeting. Holders approved the Nasdaq Proposal authorizing the issuance of up to 64,864,864 shares upon exercise of certain warrants issued on August 28, 2025. The proposal passed with 4,937,555 votes for, 1,479,087 against, and 142,257 abstentions, with 8,178,900 broker non-votes.
Stockholders did not approve changing the company name to Moleculin Inc., which required a majority of outstanding shares. The name proposal received 11,258,199 for, 843,364 against, and 2,636,236 abstentions. An adjournment proposal was approved with 5,589,386 for, 806,047 against, and 163,466 abstentions. As of August 28, 2025, there were 36,739,360 shares outstanding; 14,737,799 shares were present or represented by proxy, constituting a quorum.
Moleculin Biotech, Inc. filed a current report describing new intellectual property progress for its drug candidate Annamycin. The company announced that the Canadian Intellectual Property Office has issued a notice of intent to grant Patent Application No. 3,142,510, titled “PREPARATION OF PRELIPOSOMAL ANNAMYCIN LYOPHILIZATE.” A patent from this application is expected to be issued in the coming months, which would strengthen Moleculin’s patent protection for this formulation in Canada.
Moleculin Biotech is registering up to 64,864,864 shares of common stock for resale by selling stockholders, consisting of shares issuable upon exercise of Series F warrants issued in an August 2025 warrant inducement transaction.
Shares outstanding were 49,498,576 as of September 16, 2025. The company will not receive proceeds from resale by the selling stockholders; the company would receive proceeds only if the Warrants are exercised for cash, which at full cash exercise of the 64,864,864 Inducement Warrant Shares would yield gross proceeds of $35.7 million.
Moleculin Biotech, Inc. filed a Form S-8 registration statement to register securities for its 2024 Stock Plan, which will be used to grant equity awards to eligible participants. The company incorporates by reference its existing and future Exchange Act reports, so that ongoing public filings automatically update the information available to plan participants. The document also describes broad indemnification protections for directors, officers, employees and agents under Delaware law, the company’s charter and bylaws, and separate indemnification agreements, supported by directors’ and officers’ liability insurance.